OlympiAD final overall survival and tolerability results | 動物用藥查詢網
由MERobson著作·2019·被引用439次—Background:IntheOlympiADstudy,olaparibwasshowntoimproveprogression-freesurvivalcomparedwithchemotherapytreatmentofphysician'schoice(TPC)in ...
Background: In the OlympiAD study, olaparib was shown to improve progression-free survival compared with chemotherapy treatment of physicians choice (TPC) in patients with a germline BRCA1 and/or BRCA2 mutation (BRCAm) and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC). We now report the planned final overall survival (OS) results, and describe the most common adverse events (AEs) to better understand olaparib tolerability in this population.
Patients and methods: OlympiAD, a Phase III, randomized, controlled, open-label study (NCT02000622[1]), enrolled patients with a germline BRCAm and HER2-negative mBC who had received ≤2 lines of chemotherapy for mBC. Patients were randomized to olaparib tablets (300 mg bid) or predeclared TPC (capecitabine, vinorelbine, or eribulin). OS and safety were secondary end points.
Results: A total of 205 pa...
Olaparib for Metastatic Breast Cancer in Patients with a ... | 動物用藥查詢網
Assessment of the Efficacy and Safety of Olaparib ... | 動物用藥查詢網
OlympiAD final overall survival and tolerability results | 動物用藥查詢網
OlympiAD final overall survival and tolerability results | 動物用藥查詢網
OlympiAD | 動物用藥查詢網
OlympiAD trial | 動物用藥查詢網
The OlympiAD trial: who won the gold? | 動物用藥查詢網
高化維五○○ COFAVIT 500
高化維五○○有哪些副作用?由東盈實業股份有限公司製造的高化維五○○是治療什麼的?藥品成分是什麼?以下為大家提供詳細的「高...